Ascentage Pharma (NASDAQ: AAPG; HKG: 6855) announced that it has completed a strategic collaboration signing with Suzhou University and the First Affiliated Hospital of Suzhou University. The three parties will focus on hematologic oncology and carry out in‑depth cooperation leveraging their respective strengths, aiming to support the high‑quality development of the innovative drug industry and to help China’s original innovative drugs reach the world and benefit more patients.
Collaboration Milestone
| Item | Detail |
|---|---|
| Parties | Ascentage Pharma (NASDAQ: AAPG; HKG: 6855); Suzhou University; First Affiliated Hospital of Suzhou University |
| Agreement Type | Strategic collaboration (signing completed) |
| Announcement Date | 19 Oct 2026 |
| Therapeutic Focus | Hematologic oncology |
| Cooperation Model | In‑depth cooperation leveraging the respective strengths of industry, academia and the clinic |
| Stated Objectives | Support high‑quality development of the innovative drug industry; help China’s original innovative drugs reach the world and benefit more patients |
Collaboration Scope & Objectives
- Hematologic Oncology Focus: The partnership centers on hematologic oncology – a therapeutic area that aligns directly with Ascentage Pharma’s apoptosis‑pathway and kinase‑inhibitor pipeline strengths.
- Industry–Academia–Hospital Triad: By pairing a global biopharmaceutical company with a comprehensive university and its flagship affiliated hospital, the collaboration spans basic research, translational science and clinical investigation under one framework.
- Global Ambition: The stated goal of helping China’s original innovative drugs reach the world signals an orientation toward globally competitive, original drug discovery rather than fast‑follow development.
- Specific Programs: Concrete research projects, funding terms and timelines were not disclosed in the announcement.
Company Profile – Ascentage Pharma
- Business Model: An integrated global biopharmaceutical company dedicated to the research and development, production and commercialization of innovative drugs.
- Apoptosis Pathway Franchise: The pipeline includes inhibitors targeting key proteins in the apoptosis pathway, notably Bcl‑2 and MDM2‑p53 – mechanisms central to restoring programmed cell death in cancer, with established relevance across leukemias and lymphomas.
- Next‑Generation Kinase Inhibitors: The company is developing next‑generation inhibitors targeting kinase mutants that emerge in cancer treatment – addressing acquired resistance, a core challenge in hematologic malignancy therapy.
- Protein Degraders: A protein degrader modality extends the pipeline beyond occupancy‑based inhibition into targeted protein elimination.
Market Impact & Outlook
- Local Ecosystem Alignment: Headquartered in Suzhou, Ascentage’s partnership with Suzhou University and its First Affiliated Hospital deepens ties within one of China’s most concentrated biopharma clusters (BioBAY/Suzhou Industrial Park ecosystem).
- Clinical Trial Infrastructure: Access to the First Affiliated Hospital – a major regional clinical center – could support investigator‑initiated studies and future trial enrollment for Ascentage’s hematologic candidates.
- Pipeline Synergy: The hematology focus complements Ascentage’s Bcl‑2, MDM2‑p53 and mutant‑kinase programs, where blood cancers represent primary indication opportunities.
- Watch Items: Investors will look for announced joint research programs, sponsored clinical studies or further institutional partnerships flowing from the collaboration (none disclosed to date).
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the strategic collaboration among Ascentage Pharma, Suzhou University and the First Affiliated Hospital of Suzhou University, and the potential development of innovative drugs in hematologic oncology. Actual results may differ materially due to risks including research and clinical outcomes, regulatory requirements, implementation of collaboration programs, and competitive dynamics. The signing of a strategic collaboration does not guarantee the development or approval of any product.-Fineline Info & Tech
